Table 2.
Treatment Strategies
| JROAD‐DPC Data (N=54 369) | |
|---|---|
| Treatment during hospitalization | |
| Parenteral anticoagulation therapy with unfractionated heparin | 42 495 (78%) |
| Thrombolysisa | 4667 (8.6%) |
| Inferior vena cava filter use | 10 816 (20%) |
| Ventilator support | 1595 (6.5%) |
| Mechanical circulation supportb | 341 (1.4%) |
| Medications at discharge alive (N=51 169) | |
| Statins | 5375/51 169 (11%) |
| Antiplatelet drugsc | 3712/51 169 (7.3%) |
| Anticoagulation therapy | 38 198/51 169 (75%) |
| Warfarin | 23 191/51 169 (45%) |
| Direct oral anticoagulants (Xa inhibitors) | 14 252/51 169 (28%) |
| Edoxaban | 8260/51 169 (16%) |
| Rivaroxaban | 3373/51 169 (6.6%) |
| Apixaban | 2600/51 169 (5.1%) |
| Heparin | 504/51 169 (1.0%) |
| Others | 270/51 169 (0.5%) |
Categorical variables are presented as numbers and percentages. JROAD‐DPC indicates Japanese Registry of All Cardiac and Vascular Diseases—Diagnosis Procedure Combination.
a
Thrombolysis included tissue plasminogen activator and urokinase.
b
Mechanical circulation support included intra‐aortic balloon pumping and percutaneous cardiopulmonary support.
c
Antiplatelet drugs included aspirin, clopidogrel, ticlopidine, cilostazol, prasugrel, ticagrelor, sarpogrelate, and ozagrel.